Add To Watchlist
Share URL
About The Company
Description
Pharmena S.A.
Read More
Overview
Value
51
Growth
67
Health
25
Management
26
Analyst Opinion
69
Total
48
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Earnings growth has improved recently
- Has a low level of debt
- Has a history of share buybacks
- Has a margin-of-safety above fair value
- Low preportion of income is paid as dividend
Risk Factors
- Does not hold enough liquid assets to cover short term liabilities
- Poor overall financial health 0
Market Peers
PHR.WA
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
1275.23%
Revenue Growth (5 Year Average)
5.75%
Ratings Consensus
Buy
Share Buybacks
100.00%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
51
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 7.5 PLN
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
1.92%
PE/Earnings Growth
N/A
Price/Book
-12.23x
Growth
Growth Score
67
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 23.59% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 23.78% is higher than the market average (12.35%)
- ✘ 5 Year Average Revenue growth of 5.75% is lower than the market average (10.97%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
5.75%
Earnings Growth
23.59%
Cashflow Growth
23.78%
Health
Health Score
25
Altman Z Score
2.44
Piostroski Score
6.00
Debt/Equity
N/Ax
Current Assets/Liabilities
0.36x
Free Cashflow/Total Debt
1.89x
Debt/Capital
0.08x
Management
Management Score
26
Average Buybacks/Dilution
100.00%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
35.44%
Return On Assets
N/A
Return On Capital Employed
-1.86%
Return On Equity
N/A
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
69
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Pharmena S.A.
Currency
PLN
Beta
0.857647
Vol Avg
1601
Ceo
Mr. Konrad Palka
Cik
Cusip
Exchange
Warsaw Stock Exchange
Full Time Employees
24
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
ul. Wólczanska 178
City
Lódz
State
Country
PL
Zip
90-530
Phone
48 422 91 33 70
All financial data provided by FMP